Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online March 10, 2008
Diabetes Care 31:1170-1176, 2008
DOI: 10.2337/dc07-1960
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1960v1
31/6/1170    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Astrup, A. S.
Right arrow Articles by Rossing, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Astrup, A. S.
Right arrow Articles by Rossing, P.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pathophysiology/Complications
Original Research

Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years

Association with mortality and decline of glomerular filtration rate

Anne Sofie Astrup, MD1, Lise Tarnow, MD1, Lotte Pietraszek1, Casper G. Schalkwijk, MD1, Coen D.A. Stehouwer, MD2, Hans-Henrik Parving, MD3,4 and Peter Rossing, MD1

1 Steno Diabetes Center, Gentofte, Denmark
2 Department of Internal Medicine, Academic Hospital Maastricht, the Netherlands
3 Faculty of Health Science, Aarhus University, Aarhus, Denmark
4 Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark

Corresponding author: Anne Sofie Astrup, MD, Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark. E-mail: ansa{at}steno.dk

OBJECTIVE—We evaluated the association of biomarkers of endothelial dysfunction and inflammation with all-cause mortality and cardiovascular mortality and morbidity and decline in glomerular filtration rate (GFR) in type 1 diabetic patients.

RESEARCH DESIGN AND METHODS—We prospectively followed 199 type 1 diabetic patients with diabetic nephropathy and 192 patients with persistent normoalbuminuria. Biomarkers were measured at baseline.

RESULTS—We constructed two Z scores: the mean inflammatory Z score combined C-reactive protein, interleukin-6, soluble intercellular adhesion molecule (sICAM-1), and secreted phospholipase A2 and the mean Z score for endothelial dysfunction combined soluble vascular cell adhesion molecule 1, plasminogen activator inhibitor-1, and sICAM-1. The mean Z score of inflammatory biomarkers was associated with mortality and the combined end point in patients with diabetic nephropathy after multivariate adjustment (hazard ratio 1.7 [95% CI 1.1–2.6]; P = 0.025 and 1.5 [1.1–2.2]; P = 0.017). The mean Z score for endothelial dysfunction biomarkers was associated with mortality in a model adjusting for age and sex in patients with diabetic nephropathy (1.6 [1.0–2.3]; P = 0.031). The mean Z score for endothelial dysfunction correlated with decline in GFR (r = –0.243; P = 0.001); the correlation persisted after multivariate adjustment (coefficient –1.38 [95% CI –2.27 to –0.50]; P = 0.002).

CONCLUSIONS—Mean Z scores of inflammatory biomarkers are significantly associated with all-cause mortality and cardiovascular morbidity and mortality in patients with nephropathy after multivariate adjustment. These data suggest that the high risk of cardiovascular disease in type 1 diabetes may be explained in part by inflammatory activity. Mean Z score of endothelial dysfunction correlated after multivariate adjustment with the rate of decline in GFR.

Abbreviations: AUC, area under the receiver operating characteristic curve • GFR, glomerular filtration rate • hsCRP, high-sensitivity C-reactive protein • IL-6, interleukin-6 • PAI-1, plasminogen activator inhibitor-1 • sICAM-1, soluble intercellular adhesion molecule-1 • sPLA2, secreted phospholipase A2 • sVCAM-1, soluble vascular cell adhesion molecule-1 • TGF-β, transforming growth factor-β


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.